PRINCETON, N.J.--( BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate at the following investor conferences in February:
Guggenheim Securities SMID Cap Biotech Conference
| Date / Time: | February 5, 2025 at 10:30 AM ET |
| Format: | Presentation and 1x1 investor meetings |
| Location: | New York, NY |
| Webcast Link: | here |
Oppenheimer 35th Annual Healthcare Life Sciences Conference
| Date / Time: | February 11, 2025 at 1:20 PM ET |
| Format: | Presentation and 1x1 investor meetings |
| Location: | Virtual |
| Webcast Link: | here |
Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.